BBA
SRPT icon

Baker Bros. Advisors’s Sarepta Therapeutics SRPT Stock Holding History

Baker Bros. Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-123,456
Closed -$9.64M – 122
2022
Q1 		$9.64M Hold
123,456
– – 0.06% 68
2021
Q4 		$11.1M Buy
+123,456
New +$10.6M 0.05% 74
2021
Q2 		– Sell
-58,700
Closed -$4.38M – 127
2021
Q1 		$4.38M Buy
+58,700
New +$5.42M 0.02% 99

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Baker Bros. Advisors's SRPT Position: Q2 2022 in Review

Baker Bros. Advisors sold out of Sarepta Therapeutics (SRPT) in Q2 2022, closing a stake of 123,456 shares — an estimated $9.64M sold.

Baker Bros. Advisors first reported a position in SRPT in Q1 2021 and held it in 3 quarters. The position peaked at $11.1M in Q4 2021. 332 funds tracked by Wall St. Rank hold SRPT as of Q2 2022.

  • Baker Bros. Advisors reported no remaining Sarepta Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Baker Bros. Advisors sold 123,456 Sarepta Therapeutics shares in Q2 2022, an estimated $9.64M.
  • Baker Bros. Advisors first reported a position in Sarepta Therapeutics in Q1 2021 and held it in 3 quarters.
  • Baker Bros. Advisors's Sarepta Therapeutics position peaked at $11.1M in Q4 2021.
  • 332 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2022.

Based on Baker Bros. Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.